Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe Third Affiliated hospital of Zhejiang Chinese Medical University

About this trial

Ischemic stroke is a common clinical disease, often accompanied by dysphagia. At present, clinical treatment for patients with dysphagia after ischemic stroke is limited. The emergence of NGF has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. The main problem is that NGF is a macromolecular material with a molecular weight of 13.4 KD, which is difficult to penetrate the blood brain barrier. A large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce NGF into the brain. Therefore, the purpose of this study is to investigate the effect of specific mode electroacupuncture stimulation combined with NGF treatment on patients with dysphagia after ischemic stroke and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional Chinese and Western medicine.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with first-ever ischemic stroke confirmed by Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI);

Onset time ranged from 15 days to 180 days;

Aged 18 to 80 years old, male or female;

Dysphagia confirmed by a videofluoroscopic swallowing study (VFSS);

Disqualifiers

Patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke;

Patients with severe cognitive impairment;

Patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities;

Patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Nerver growth factor (NGF) injection

    Drug

    The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.

  • Placebo injection

    Drug

    Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.

  • EA intervention

    Device

    Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20(Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of "De Qi"). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of patient can tolerate, targeting a current strength of 3.0mA, for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks.

  • Acupuncture intervention

    Device

    Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20(Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of "De Qi"). Then, the needles are connected to an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) without closed circuit, with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks.

Treatment groups

144 Participants
are divided into 4 treatment groups
Group A: EA + NGF groupExperimental treatment 2 interventions
Group B: EA + placebo groupPlacebo comparator 2 interventions
Group C: Acupuncture + NGF groupSham comparator 2 interventions
Group D: Acupuncture + placebo groupSham comparator 2 interventions

Trial outcomes

Primary outcomes

1

Functional Oral Intake Scale (FOIS)

Time frame
week 0, week 2, week 4, week 6, week 12

Secondary outcomes

1

Dysphagia Outcome and Severity Scale (DOSS)

Time frame
week 0, week 6
2

Penetration Aspiration Scale (PAS)

Time frame
week 0, week 6
3

modified Rankin Scale (mRS)

Time frame
week 0, week 2, week 4, week 6
4

Modified Barthel Index (MBI)

Time frame
week 0, week 2, week 4, week 6

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.